OncoTherapy Science, Inc. 4564.T Stock
OncoTherapy Science, Inc. Price Chart
OncoTherapy Science, Inc. 4564.T Financial and Trading Overview
| OncoTherapy Science, Inc. stock price | 19 JPY |
| Previous Close | 41 JPY |
| Open | 43 JPY |
| Bid | 43 JPY x 0 |
| Ask | 44 JPY x 0 |
| Day's Range | 42 - 45 JPY |
| 52 Week Range | 34 - 69 JPY |
| Volume | 5.16M JPY |
| Avg. Volume | 2.46M JPY |
| Market Cap | 8.89B JPY |
| Beta (5Y Monthly) | 0.567816 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.75 JPY |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
4564.T Valuation Measures
| Enterprise Value | 7.36B JPY |
| Trailing P/E | N/A |
| Forward P/E | -2.1078432 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 7.8393474 |
| Price/Book (mrq) | 9.699977 |
| Enterprise Value/Revenue | 6.49 |
| Enterprise Value/EBITDA | -6.745 |
Trading Information
OncoTherapy Science, Inc. Stock Price History
| Beta (5Y Monthly) | 0.567816 |
| 52-Week Change | -33.87% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 69 JPY |
| 52 Week Low | 34 JPY |
| 50-Day Moving Average | 38.6 JPY |
| 200-Day Moving Average | 52.95 JPY |
4564.T Share Statistics
| Avg. Volume (3 month) | 2.46M JPY |
| Avg. Daily Volume (10-Days) | 4.3M JPY |
| Shares Outstanding | 192.64M |
| Float | 165.8M |
| Short Ratio | N/A |
| % Held by Insiders | 22.49% |
| % Held by Institutions | 5.13% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 500:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | -98.58% |
| Operating Margin (ttm) | -97.61% |
| Gross Margin | -59.61% |
| EBITDA Margin | -96.20% |
Management Effectiveness
| Return on Assets (ttm) | -32.97% |
| Return on Equity (ttm) | -78.92% |
Income Statement
| Revenue (ttm) | 1.13B JPY |
| Revenue Per Share (ttm) | 5.89 JPY |
| Quarterly Revenue Growth (yoy) | -46.80% |
| Gross Profit (ttm) | N/A |
| EBITDA | -1091000064 JPY |
| Net Income Avi to Common (ttm) | -1118000000 JPY |
| Diluted EPS (ttm) | -6.94 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.12B JPY |
| Total Cash Per Share (mrq) | 5.8 JPY |
| Total Debt (mrq) | 0 JPY |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 2.335 |
| Book Value Per Share (mrq) | 4.433 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -794000000 JPY |
| Levered Free Cash Flow (ttm) | -231875008 JPY |
Profile of OncoTherapy Science, Inc.
| Country | Japan |
| State | N/A |
| City | Kawasaki |
| Address | 1-2 Higashida-cho |
| ZIP | 213-0012 |
| Phone | 81 4 4201 6429 |
| Website | https://www.oncotherapy.co.jp |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its clinical development product pipeline includes small-molecule drugs, such as OTS167, a maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer. The company's clinical development product pipeline also comprise cancer- specific peptide vaccines, including S-588410, which is in Phase III clinical trials for the treatment esophageal cancer, as well as in Phase II clinical trials for the treatment of bladder cancer; S-488210 that is in Phase I/II clinical trials for the treatment of head and neck cancer; and S-588210, which is in Phase I clinical trials for the treatment of solid tumor. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and KHK6640, an anti-amyloid beta peptide antibody that is Phase I clinical trials for Alzheimer's disease. The company was incorporated in 2001 and is headquartered in Kawasaki, Japan.
Q&A For OncoTherapy Science, Inc. Stock
What is a current 4564.T stock price?
OncoTherapy Science, Inc. 4564.T stock price today per share is 19 JPY.
How to purchase OncoTherapy Science, Inc. stock?
You can buy 4564.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for OncoTherapy Science, Inc.?
The stock symbol or ticker of OncoTherapy Science, Inc. is 4564.T.
Which industry does the OncoTherapy Science, Inc. company belong to?
The OncoTherapy Science, Inc. industry is Biotechnology.
How many shares does OncoTherapy Science, Inc. have in circulation?
The max supply of OncoTherapy Science, Inc. shares is 217.64M.
What is OncoTherapy Science, Inc. Price to Earnings Ratio (PE Ratio)?
OncoTherapy Science, Inc. PE Ratio is now.
What was OncoTherapy Science, Inc. earnings per share over the trailing 12 months (TTM)?
OncoTherapy Science, Inc. EPS is -5.75 JPY over the trailing 12 months.
Which sector does the OncoTherapy Science, Inc. company belong to?
The OncoTherapy Science, Inc. sector is Healthcare.